NFKBIA (Gene)

Organism:

Homo sapiens

Synonyms:EDAID2, ENTREZ:4792, HGNC:7797, IKBA, MAD-3, MIM:164008, NFKB inhibitor alpha, NFKBI, NFKBIA, NM_020529, NP_065390

Omim:OMIM:164008

Id:ENSG00000100906

Hgnc:HGNC:7797

Entrez:4792

Ensembl:ENSG00000100906

Description:NFKB inhibitor alpha

This gene encodes a member of the NF-kappa-B inhibitor family, which contain multiple ankrin repeat domains. The encoded protein interacts with REL dimers to inhibit NF-kappa-B/REL complexes which are involved in inflammatory responses. The encoded protein moves between the cytoplasm and the nucleus via a nuclear localization signal and CRM1-mediated nuclear export. Mutations in this gene have been found in ectodermal dysplasia anhidrotic with T-cell immunodeficiency autosomal dominant disease. [provided by RefSeq, Aug 2011]

Analyze

CFDE DD-Knowledge Graph

The CFDE Data Distillery Knowledge Graph contains entities and relationships across the CFDE. View NFKBIA's neighborhood in the knowledge graph.

Submit

Playbook Workflow Builder: Gene-Centric Workflow

View Gene-Centric information about the gene from a pre-built PWB workflow. View the workflow with NFKBIA.

CFDE Gene-Centric Appyter

The CFDE Gene Centric Appyter Resolves and Displays Gene-Centric information from CFDE APIs. Execute the Appyter using NFKBIA.

Submit

GDLPA Landing Pages Links

The Gene and Drug Landing Page Aggregator (GDLPA) finds links to primary and secondary source information from CFDE and other resources. Discover landing pages for NFKBIA.

Submit

Playbook Workflow Builder

The Playbook Workflow Builder helps you interactively construct workflows leveraging CFDE APIs without code. Start a new workflow with NFKBIA.

Results found

Linked to

	Label	Description
	GSE135514 8 V 7 DASATINIB HUMAN DN Gene Set (Entity type)	A Gene Set from LINCS
	GSE145990 1 V 0 IBRUTINIB HUMAN UP Gene Set (Entity type)	A Gene Set from LINCS
	GSE199688 artemisinin 0 v 1 human dn Gene Set (Entity type)	A Gene Set from LINCS
	GSE216043 10 V 5 CISPLATIN HUMAN UP Gene Set (Entity type)	A Gene Set from LINCS
	GSE114492 GSE153671 KMT2D inhibition 6 v 8 human up Gene Set (Entity type)	A Gene Set from LINCS
	GSE197555 0 V 3 TRAMETINIB HUMAN UP Gene Set (Entity type)	A Gene Set from LINCS
	GSE152441,GSE152442 6 V 4 FOLIC ACID HUMAN UP Gene Set (Entity type)	A Gene Set from LINCS
	GSE168401 2 V 0 HARMINE HUMAN DN Gene Set (Entity type)	A Gene Set from LINCS
	GSE116810 5 V 1 SELINEXOR HUMAN UP Gene Set (Entity type)	A Gene Set from LINCS
	GSE216988 GSE216989 decitabine 0 v 1 human up Gene Set (Entity type)	A Gene Set from LINCS

GSE135514 8 V 7 DASATINIB HUMAN DN

Gene Set (Entity type)

A Gene Set from LINCS

GSE145990 1 V 0 IBRUTINIB HUMAN UP

Gene Set (Entity type)

A Gene Set from LINCS

GSE199688 artemisinin 0 v 1 human dn

Gene Set (Entity type)

A Gene Set from LINCS

GSE216043 10 V 5 CISPLATIN HUMAN UP

Gene Set (Entity type)

A Gene Set from LINCS

GSE114492 GSE153671 KMT2D inhibition 6 v 8 human up

Gene Set (Entity type)

A Gene Set from LINCS

GSE197555 0 V 3 TRAMETINIB HUMAN UP

Gene Set (Entity type)

A Gene Set from LINCS

GSE152441,GSE152442 6 V 4 FOLIC ACID HUMAN UP

Gene Set (Entity type)

A Gene Set from LINCS

GSE168401 2 V 0 HARMINE HUMAN DN

Gene Set (Entity type)

A Gene Set from LINCS

GSE116810 5 V 1 SELINEXOR HUMAN UP

Gene Set (Entity type)

A Gene Set from LINCS

GSE216988 GSE216989 decitabine 0 v 1 human up

Gene Set (Entity type)

A Gene Set from LINCS

DISPLAY PER PAGE

CFDE Workbench

Consortium

Community

Resources

@CFDE Workbench 2026

The CFDE Workbench is actively being developed and maintained by the CFDE Data Resource Center (DRC).The DRC is funded by OT2OD036435 from the Common Fund at the National Institutes of Health.

Consortium

Community

Resources

CFDE Workbench

The CFDE Workbench is actively being developed and maintained by the CFDE Data Resource Center (DRC).The DRC is funded by OT2OD036435 from the Common Fund at the National Institutes of Health.

@CFDE Workbench 2026

This repository is under review for potential modification in compliance with Administration directives.